Matchmaker Project → CDMO suitability · live data Describe your manufacturing program — capability, therapeutic area, geography, technology platforms, fill-finish and quality — and your real CDMO records re-rank live by a transparent six-factor weighted estimate. Regulatory and inspection standing is deliberately not one of the six: see cited inspection records for the published certificates a company actually holds.
Manufacturing capability Any Small molecules HPAPI Peptides Oligonucleotides Biologics mRNA Plasmid DNA Sterile injectables Ophthalmics Vaccines Oral solids Liquids Semi-solids Cell therapy Gene therapy Viral vectors CAR-T Exosomes Radiopharmaceuticals Lyophilization Controlled substances Combination products Process development Clinical manufacturing Commercial manufacturing Packaging Technology transfer Therapeutic area Any Oncology Biologics Vaccines Cell & gene therapy Sterile injectables Rare disease mRNA Radiopharmaceuticals Ophthalmics Geography Any ADC plant) and Rockville Anthoussa Arklow (Ireland) Asia Asia (6 sites Aurora IL) and Italy (Pessano and San Giuliano Australia Austria (Rankweil) and the USA (Chicago) Avlonas 48 Avlonas 49 Banyeres del Penedès Barcelona) Basque Country) Belgium Berlin Bidar manufacturing) Bio Campus II Bloomington Boston Boston MA) Bristol PA) and United Kingdom (Cambridge) CA) and Europe (Etten-Leur CGMP facilities across four countries: United States (California Cairo (Egypt) and Nouasseur (Morocco) California (Tustin and Costa Mesa) California) and Asia Canada Canada (Candiac CDMO site and Montreal laboratories); states clients from 16 different countries Canada (Mississauga Canada (Montréal); Canada-wide clinical trial distribution Canada — serving an international client base Canada; company states 100+ active clients across five geographic markets Caponago) Changzhou Cheongju China China (Jinxi Health Biological Industrial Park China (Shanghai) and the USA (North Augusta China and Singapore China; Europe Innovation Hub in Basel Chungcheongbuk-do Colombia Colorado; The Woodlands Development & Manufacturing Campus in Wuhan Drug substance manufacturing in Spain (Leon) and Argentina (Garin Dublin) EU and Japan East Windsor New Jersey (USA) and Cork (Ireland); R&D centre in Shanghai; offices including Hong Kong Ettingen Europe Europe (France Europe and India/Asia Europe and North America; sites include France Europe and other markets; named sites include Grand Island (USA) Europe and the United States; sites in Belgium Europe — Neu-Ulm (HQ) Exports under its own brand to over 80 countries Finland Five facilities in Bengaluru Florida; Gainesville Foshan; Hong Kong Science Park office Four sites: Fontenay-sous-Bois France France (Chenôve) France (Corbeil-Essonnes) and South Korea (Daejeon France (EU) France (x2) and Germany France) Fribourg Georgia Germany Germany (Ennigerloh) with a US sales subsidiary; supplies pharmaceutical and biotechnology companies internationally Germany (Frankfurt Germany (Homburg Germany and United States; company states 180+ clients worldwide Germany-based Gipuzkoa Global operations across Europe and the U.S.; J.POD biologics manufacturing facilities in Redmond Grafing and Waltrop in Germany Greece Guangzhou HQ and R&D site (Huangpu District); Penglai industrial site Guangzhou; Kunlun industrial site Herouville-Saint-Clair and Osny (France) and Braine-l'Alleud (Belgium) Illinois) supplying globally Incheon (Bio Campus I India India (Chakan and Bhosari India (Hyderabad R&D campus India-based Indiana Indiana (USA) and Halle/Westfalen (Germany); states products distributed in 120+ countries Integrated network of facilities across North America Ireland Ireland (Swords Ireland and United States Isola della Scala (Italy) Italy Italy (Bergamo Jacarepaguá (Brazil) Japan Japan and China Jinhua City Korea Langenargen) Lecong Town Lenexa KS Liestal) Lithuania Lithuania (EU) and Waltham Lliçà de Vall Locations in Belgium Luxembourg MA MA (USA) MD; Maple Grove MN); supplies drug product to more than 100 countries MO Macau Madrid) Manufacturing and development based in Bengaluru Manufacturing in Songdo Manufacturing plants in Loures (Portugal) Manufacturing sites in Pamplona-Noain (Spain) and Turku (Finland) Maryland; regional offices in Ridgefield Park NJ Massachusetts Massachusetts (US) Mexico and the USA Michigan Milan); supplies more than 80 international markets More than 17 manufacturing and R&D sites for contract manufacturing across North America Moscow (Russia) Mumbai and Japan Munich Munro); global headquarters in Madrid with further offices in Lugano NH NJ NV Netherlands Netherlands) New Jersey New Jersey); the company states expansion into the USA and Europe New York) Nine cGMP sites across Taiwan (Tainan Nine manufacturing plants No. 788 Yonghu Street North America North America (Middletown DE North America and Asia — sites listed in Switzerland (Basel North America and Asia; UK North Carolina North Carolina; Boulder and Louisville Norway Norway — sites at Elverum (liquid formulations) and Ås (biologics/Diatec); states it serves partners globally Norway); serves more than 70 end markets globally ON) and the United States (Baltimore Oceania Operations in China Operations in Prince Edward Island and Nova Scotia Oregon; Clearwater PA Pennsylvania) Perth); Perth site states supply of over 600 approved products to more than 140 countries Plankstadt) Poland Poland (Poznań) Portugal (Lisbon) Production and development sites in Germany (Ravensburg Puerto Rico Puerto Rico (Arecibo) and Italy (Liscate) Pune) and United States (Pennington Quebec SC Saarland) and Italy (Baranzate San Diego CA San Diego CA) and Europe (Couvet Scotland Sejong) Seven facilities: Durham and Research Triangle Park Shanghai Jinshan Shunde District Singapore Singapore) Single US manufacturing site (Woodstock Single campus in Fishers Single campus in Grand Rapids Single-city operation in Stirling Sites in Dessau-Rosslau and Magdeburg Sites in Greece (Alimos/Athens Sites located across Europe Six industrial sites across three continents — Spain (Celrà Sofgen Pharma operates directly in 13 countries across the Americas; B2B reach stated as more than 50 countries worldwide South America South Carolina) South Korea South Korea (Seoul headquarters; Songdo campus under construction) and the United States (Syracuse South Korea and China Spain Spain (Alcorcón Spain (Hernani Spain and Sweden Spain and the USA Spain; products supplied to markets worldwide States 16 manufacturing sites worldwide and products served to 150 countries; named manufacturing locations include Gidy and Bolbec (France) Supplies customers in Germany and abroad from its Hennigsdorf (near Berlin) headquarters Sweden Switzerland Switzerland and Azuqueca de Henares Switzerland) Switzerland; China Innovation Hub in Shanghai Switzerland; and Leuven TN Taiwan Taiwan (Xizhi and Zhubei manufacturing facilities); European presence via EirGenix Europe GmbH Taixing and Tuas Tangxi Town Taoyuan Texas Texas (307 E. Josephine St.) Texas) Texas; Geneva Thiva) Tianjin (China) Tokyo and Amsterdam Tokyo and Barcelona Toledo (Spain) Two Australian sites (Adelaide Two Swiss locations (Basel and Visp) serving clients worldwide; commercial office opened in Tokyo Two campuses in Osong Two manufacturing sites in Poland: Gdansk and Warsaw-Duchnice. Two sites in Sweden: Matfors (Sundsvall) and Solna (Stockholm) Two sites — Whippany Two sites: Spokane UK UK) and India US (Pennsylvania USA USA and Kirkland USA and Mirabel United Kingdom United Kingdom (Manchester) and United States (Greater Boston); customers across the US United States United States (Cranbury NJ United States (Illinois United States (NC United States (Oklahoma) United States (Philadelphia PA United States (Raleigh NC corporate HQ United States and France United States and United Kingdom (10 manufacturing and R&D sites) United States only - Bend United States only — two campuses in Orange County United States — the current site lists only San Antonio United States; states an open bonded warehouse location in Switzerland for international supply chain services Uppsala and Brunna (Sweden) Vandalia OH Vilnius Warsaw/Anpharm (Poland) Washington Washington (US) and Toulouse Worcester MA Wuxi City Zhejiang) Zhongli Zhunan) and Europe (Germany and India and North America; sites in Greece and Sophia Antipolis in France; the site also references a new facility in Hyderabad as part of a global WuXi Biologics network across the US cGMP facility network across Europe four logistics sites and eight development centres across Europe (Germany including Shanghai Waigaoqiao near Milan); products sold in more than 100 countries plus a Seoul office; serves domestic and global clients plus a commercial office in Boston plus a sales office in the United States serving domestic and export markets worldwide serving global biopharmaceutical customers serving global markets serving international clients serving partners in North America serving the global biopharmaceutical market the Netherlands (x2) the Netherlands and Canada the US and Asia the United States and the United Kingdom with a stated global distribution network in over 100 countries with offices in Munich with sales offices in the USA Fill-finish Any Vial filling Syringe filling Cartridge filling Blow-fill-seal Isolator filling RABS filling Min quality score Any quality ≥ 75 ≥ 85 ≥ 90 ≥ 95
Required technology platforms
Mammalian cell culture Microbial fermentation Viral vector production mRNA/LNP Continuous manufacturing Single-use systems Spray drying Hot-melt extrusion
Factor weights · Σ 100
fixed Manufacturing capability 26
Therapeutic experience 17
Geography 17
Technology platforms 14
Fill-finish capability 14
Quality & availability 12
Score = Σ factor credit (weights sum to 100). Capability / therapeutic / fill-finish use exact membership; technology gives proportional credit; an “Any” field is non-constraining. Nothing here scores a CDMO on regulatory or inspection standing — see
cited inspection records . Fully transparent & reproducible — not a recommendation to engage.
100 CDMOs ranked across 0 active requirements
Weighted estimate over real CDMO records, not a recommendation to engage · scores deterministic, rules-based — not AI · no factor scores regulatory or inspection standing.